Provider: - Institution: - Data provided by Europeana Collections- Οι αχώριστοι- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal ...Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain ...Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- "Θέλω να γίνω πιλότος όταν μεγαλώσω", δήλωσε η Τζίνα στην οικογένειά της, και περίμενε να μείνουν όλοι με το στόμα ανοιχτό. Κανείς ...όμως δεν της έδωσε σημασία, κανείς δεν την πήρε στα σοβαρά. Αλλά η Τζίνα είναι αποφασισμένη να πετάξει κάποια μέρα πάνω από τα σύννεφα. Μοναδικός σύμμαχος ο παππούς της, που ονειρευόταν κι αυτός κάποτε να γίνει πιλότος. Όταν όμως το κρυμμένο όπλο του κάνει φτερά, η Τζίνα θα αναγκαστεί να βάλει στην άκρη για λίγο τ' όνειρό της...- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain ...Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain ...Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain ...Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type ...1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs.
In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing group). We randomly assigned 757 patients with a median CD4 count of 191 cells per cubic millimeter and a median HIV-1 RNA level of 4.8 log10 copies per milliliter to the three groups.
At a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than in the lopinavir-ritonavir group (P=0.006) but was not significantly different in the NRTI-sparing group from the time in either of the other two groups. At week 96, the proportion of patients with fewer than 50 copies of plasma HIV-1 RNA per milliliter was 89% in the efavirenz group, 77% in the lopinavir-ritonavir group, and 83% in the NRTI-sparing group (P=0.003 for the comparison between the efavirenz group and the lopinavir-ritonavir group). The groups did not differ significantly in the time to discontinuation because of toxic effects. At virologic failure, antiretroviral resistance mutations were more frequent in the NRTI-sparing group than in the other two groups.
Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group. The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance. (ClinicalTrials.gov number, NCT00050895 ClinicalTrials.gov.).
Histopathology laboratories devote considerable time and effort to sorting tissue sample slides. We observed slide sorting in a typical urban hospital to understand the existing workflow and explore ...how it might be supported by an interactive computer support system. We observed 8.5 hours of slide sorting activity through a video camera mounted above a laboratory workbench. Through detailed video analysis, we characterised the process, examined which activities took the most time, and explored design considerations. We found that a very large proportion (23.5%) of the slide sorting time involved managing paper documents. We suggest that an interactive computer support system could automatically detect which slides are sorted into which folders and digitally list additional slides to include with these sets; this would support the workflow of technicians, while eliminating paper management and manual barcode reading operations, leading to time savings of approximately 30%. Additional recommendations for the design of such a support system include focusing on case management (e.g. how many slides belong to each case, whether a complete case will fit within the current folder, and which slides associated with a case are still missing), supporting recovery from disruptions, and enabling a flexible rather than a highly scripted workflow.
PDF
